A Dose-escalation Study to Evaluate the Safety, Tolerability, and Antitumor Activity of MEDI-573 in Subjects With Advanced Solid Tumors

Inclusion Criteria:

- Histologically confirmed advanced solid tumor for which no curative or standard
therapies exist.

- Karnofsky Performance Status ≥60.

- Adequate hematological function.

- Adequate organ function.

- Women of non-child-bearing potential (defined as being >1 year post-menopausal) or
using effective contraception, e.g., use of oral contraceptives with an additional
barrier method (since the investigational product may impair the effectiveness of oral
contraceptives), double barrier methods (diaphragm with spermicidal gel or condoms
with contraceptive foam), Depo-Provera, partner vasectomy, or total abstinence, from
the time the informed consent is signed through 30 days after the last dose of
MEDI-573. Male subjects with partners of child-bearing potential must be surgically
sterile or use contraceptive method as described above from the time of the initiation
of MEDI-573 through 30 days after the last dose of MEDI-573.

Exclusion Criteria:

- No prior treatment within 4 weeks of study drug administration.

- No concurrent therapy for treatment of cancer.

- No uncontrolled diabetes.

- New York Heart Association Grade ≥ 2 congestive heart failure.

- History of myocardial infarction, unstable angina, transient ischemic attack or stroke
within the previous 6 months prior to study entry.

- Documented brain metastasis.

- Pregnancy or lactation or plans to become pregnant while on study.

- Clinically significant abnormality on ECG.